



DAFTAR PUSTAKA

1. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. *Dig Dis Sci*. 2013;58(2):519–25.
2. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohn's Colitis*. 2014;8(10):1179–207.
3. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: A population-based epidemiological study. *Inflamm Bowel Dis*. 2013;19(6):1218–23.
4. Setty M, Russell GH, Bousvaros A. Clinical manifestation of Crohn disease in children and adolescents. *UpToDate*. 2016.
5. Bousvaros A. Overview of the management of Crohn disease. *UpToDate*. 2018.
6. Prasetyo D. Inflammatory Bowel Diseases. In: *Buku Ajar Gastroenterohepatologi. UKK-Gastroenterologi-hepatologi IDAI*; 2009.
7. Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. *Am J Gastroenterol*. 2008;103(8):2092–8.
8. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. *Inflamm Bowel Dis*. 2011;17(6):1314–21.
9. Claar RL, Tilburg M, Abdullah B, Langer S, Sherif D, Whitehead WE, et al. Psychological Distress and Quality of Life in Pediatric Crohn Disease : Impact of Pain and Disease State. *JPGN*. 2017;65(4):420–4.
10. Schaefer ME, Conklin L. Changing Paradigms for Assessing Response to Therapy in Crohn's Disease. *NASPGHAN*. 2014;1–16.
11. Kreijne J, Lie M, Vogelaar L, Woude C. Practical Guideline For Fatigue Management In Inflammatory Bowel Disease. *J Crohn's Colitis*. 2015;313(2):244–53.
12. Rachmilewitz D, Lichtiger S, Haens GD, Ph D, Diamond RH, Broussard DL, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. *N Engl J Med*. 2010;363(11):1086–8.



13. Schaefer ME, Machan JT, Kawatu D, Langton CR, Markowitz J, Crandall W, et al. Factors that determine risk for surgery in pediatric patients with crohn's disease. *Clin Gastroenterol Hepatol*. 2010;8(9):789-794.e2.
14. Cheifetz AS. Management of Active Crohn Disease. Vol. 02215, *The Journal of American medical Association*. 2013.
15. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease. *Gastroenterology*. 2010;138(2):463–8.
16. Dave M, Loftus E V. Mucosal healing in inflammatory bowel disease - A true paradigm of success? *Gastroenterol Hepatol*. 2012;8(1):29–38.
17. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. *Clin Gastroenterol Hepatol*. 2015;13(6):1042-1050.e2.
18. Cheifetz AS, Cullen GJ. Sulfasalazine and 5 aminosalicylates in the treatment of inflammatory bowel diaseas. *UpToDate*. 2018.
19. Bousvaros A, Turner D, Vitito L, Greifer M, Jenkins J. Monitoring Disease Activity in Pediatric IBD Patients. *A Contin Med Educ Monogr Ser by NASPGHAN CDHNF*. 2009;1–11.
20. Arya A V., Rostom A, Dong WF, Flynn AN. Crohn's disease exacerbation induced by *Edwardsiella tarda* gastroenteritis. *Case Rep Gastroenterol*. 2011;5(3):623–7.
21. Mudireddy P, Scott F, Feathers A, Lichtenstein GR. Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions. Vol. 23, *Inflammatory Bowel Diseases*. 2017. hal. 1832–9.
22. Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, et al. Risk factors for rehospitalization within 90 days in patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2015;21(11):2583–9.
23. Gasparetto M, Guariso G. Crohn's disease and growth deficiency in children and adolescents. *World J Gastroenterol*. 2014;20(37):13219–33.
24. Teitelbaum J. Growth failure and poor weight gain in children with inflammatory bowel disease. *UpToDate*. 2017.
25. Rufo PA. Important health maintenance issues for children and adolescents with



- inflammatory bowel disease. UpToDate. 2018;
26. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn's disease: A systematic review and meta-analysis. *World J Gastroenterol*. 2013;19(24):3866–71.
 27. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. *Inflamm Bowel Dis*. 2008;14(6):839–49.
 28. Wong SC, MacRae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. *J Pediatr Gastroenterol Nutr*. 2006;43(2):144–55.
 29. Ley D, Duhamel A, Behal H, Vasseur F, Sarter H, Michaud L, et al. Growth pattern in paediatric Crohn's disease is related to inflammatory status Delphine. *J Pediatr Gastroenterol Nutr*. 2016.
 30. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. *Gastroenterology*. 2002;122(6):1592–608.
 31. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. *Pediatr Res*. 2008;64(6):673–6.
 32. Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, et al. Whole body BMC in pediatric Crohn disease: Independent effects of altered growth, maturation, and body composition. *J Bone Miner Res*. 2004;19(12):1961–8.
 33. Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. *Am J Physiol Regul Integr Comp Physiol*. 2001;281:R1483–91.
 34. Chawla N, Deshmukh M, Sharma A, Patole S, Journal J, Gastroenterology P, et al. Which PCDAI version best reflects intestinal inflammation in pediatric Crohn's disease? *J Pediatr Gastroenterol Nutr*. 2016.
 35. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. *Inflamm Bowel Dis*. 2012;18(1):55–62.
 36. Mulyani NS, Juffrie M, Kristiani D, Rosalina I, Kadim M, Hartyanto I, et al. Modul



- Pelatihan Perdarahan Saluran Cerna Pada Anak. 1 ed. Mulyani NS, Juffrie M, Oswari H, editor. UKK Gastro-Hepatologi IDAI; 2010.
37. Lestari ED. Nutrisi enteral. In: Sjarif DR, Lestari ED, Mexitalia M, Nasar SS, editor. Buku Ajar Nutrisi Pediatrik dan Penyakit Metabolik. 1 ed. Jakarta: Badan Penerbit IDAI; 2014;51–65.
38. Gradel KO, Nielsen HL, Schønheyder HC, Ejlersen T, Kristensen B, Nielsen H. Increased Short- and Long-Term Risk of Inflammatory Bowel Disease After Salmonella or Campylobacter Gastroenteritis. *Gastroenterology* [Internet]. 2009;137(2):495–501.
39. Batubara JRL. Adolescent Development (Perkembangan Remaja). *Sari Pediatr.* 2010;12(1):21–9.
40. Marcus SB, Strople JA, Neighbors K, Benchell JW, Nelson SP, Limbers C, et al. Fatigue and Health-Related Quality of Life in Pediatric Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol.* 2009;7(5):554–61.